TY - JOUR
T1 - The landscape of new drugs in lymphoma
AU - Younes, Anas
AU - Ansell, Stephen
AU - Fowler, Nathan
AU - Wilson, Wyndham
AU - de Vos, Sven
AU - Seymour, John
AU - Advani, Ranjana
AU - Forero, Andres
AU - Morschhauser, Franck
AU - Kersten, Marie Jose
AU - Tobinai, Kensei
AU - Zinzani, Pier Luigi
AU - Zucca, Emanuele
AU - Abramson, Jeremy
AU - Vose, Julie
PY - 2017
Y1 - 2017
N2 - The landscape of drugs for the treatment of lymphoma has become crowded in light of the plethora of new agents, necessitating the efficient prioritization of drugs for expedited development. The number of drugs available, and the fact that many can be given for an extended period of time, has resulted in the emergence of new challenges; these include determining the optimal duration of therapy, and the need to balance costs, benefits, and the risk of late-onset toxicities. Moreover, with the increase in the number of available investigational drugs, the number of possible combinations is becoming overwhelming, which necessitates prioritization plans for the selective development of novel combination regimens. In this Review, we describe the most-promising agents in clinical development for the treatment of lymphoma, and provide expert opinion on new strategies that might enable more streamlined drug development. We also address new approaches for patient selection and for incorporating new end points into clinical trials
AB - The landscape of drugs for the treatment of lymphoma has become crowded in light of the plethora of new agents, necessitating the efficient prioritization of drugs for expedited development. The number of drugs available, and the fact that many can be given for an extended period of time, has resulted in the emergence of new challenges; these include determining the optimal duration of therapy, and the need to balance costs, benefits, and the risk of late-onset toxicities. Moreover, with the increase in the number of available investigational drugs, the number of possible combinations is becoming overwhelming, which necessitates prioritization plans for the selective development of novel combination regimens. In this Review, we describe the most-promising agents in clinical development for the treatment of lymphoma, and provide expert opinion on new strategies that might enable more streamlined drug development. We also address new approaches for patient selection and for incorporating new end points into clinical trials
U2 - https://doi.org/10.1038/nrclinonc.2016.205
DO - https://doi.org/10.1038/nrclinonc.2016.205
M3 - Review article
C2 - 28031560
SN - 1759-4774
VL - 14
SP - 335
EP - 346
JO - Nature reviews. Clinical oncology
JF - Nature reviews. Clinical oncology
IS - 6
ER -